2-FXE EU

2F-2′-Oxo-PCE, commonly referred to as 2-FXE, is a dissociative compound belonging to the arylcyclohexylamine class. This research chemical is a fluorinated derivative of deschloroketamine (DCK) and is structurally related to compounds like ketamine and methoxetamine (MXE). Its molecular formula is C13H17FNO, featuring a fluorine atom substitution that alters its binding affinity and pharmacological effects compared to its analogs.

Mechanism of Action: 2F-2′-Oxo-PCE primarily acts as an NMDA receptor antagonist, disrupting the action of glutamate, an excitatory neurotransmitter in the central nervous system. This mechanism induces dissociative effects, characterized by altered sensory perception, detachment from reality, and a reduction in pain sensitivity. The fluorine substitution potentially enhances lipophilicity and receptor binding, contributing to its unique profile.

Effekter:

• Dissociation: Users report a profound sense of detachment from their body and surroundings. The experience can range from mild separation to full immersion in a dissociative state, often described as the “K-hole” effect.
• Eufori: At moderate doses, 2F-2′-Oxo-PCE can produce a sense of well-being and pleasure.
• Altered Perception: Users may experience changes in auditory and visual processing, including distortions and hallucinations.
• Cognitive Effects: These include impaired memory, reduced attention span, and slowed thought processes.

Dosage Guidelines: Dosage is highly variable depending on individual tolerance, experience, and sensitivity. Standard guidelines are as follows:

• Threshold Dose: 2-5 mg
• Light Dose: 5-10 mg
• Common Dose: 10-20 mg
• Strong Dose: 20-30 mg
• Heavy Dose: 30 mg+

It is essential to start with a low dose to gauge individual sensitivity due to the variability in effects and potential for unexpected reactions.

Onset, Duration, and Half-Life:

• Onset: 20-40 minutes (oral), 5-15 minutes (intranasal)
• Peak: 1-2 hours
• Duration: 3-6 hours
• Half-Life: Estimated at 6-8 hours

Biverkningar:

• Physical: Dizziness, nausea, vomiting, blurred vision, and motor impairment. Prolonged or heavy use may result in bladder dysfunction or “ketamine bladder syndrome.”
• Cognitive: Confusion, paranoia, and dissociation. In some cases, users report persistent changes in perception or memory impairment.
• Psychological: Anxiety or panic, especially at higher doses or in unfamiliar settings.

Harm Reduction Guidelines:

• Start with a low dose and wait for effects to manifest before redosing.
• Avoid combining with other substances, particularly depressants like alcohol or benzodiazepines, which can increase the risk of respiratory depression.
• Use in a safe, controlled environment with a sober sitter if possible.
• Stay hydrated and monitor urinary health, particularly with regular use.
• Limit frequency of use to reduce the risk of dependency and physical harm.

Legal and Ethical Considerations: 2F-2′-Oxo-PCE is a research chemical and may not be approved for human consumption in certain jurisdictions. Users must ensure compliance with local laws and prioritize safety in experimental settings.